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Rnitinol-based, self-expanding stents for the treatment of iliac lesions similar to those
in this study. Core laboratories were utilized for independent conﬁrmation of angi-
ography and duplex ultrasound ﬁndings. All site reported MAEs were adjudicated by
an independent Clinical Events Committee.
RESULTS For the BIOFLEX-I study of patients with iliac disease treated with the
Astron stent, the primary endpoint was met. The 12-month composite endpoint of
MAE was 2.1% (3/146) (p<0.001) 95 % CI [0.4%, 5.9%]. The 30 day mortality rate was
0.7% (1/146) 95 % CI [0.0%, 3.8%]. Target lesion revascularization (TLR) rates at 12
months were 1.4% (2/146) 95 % CI [0.2%, 4.5%], and 12-month index limb amputation
was 0.0% (0/146) 95 % CI [0.0%, 2.5%]. The secondary endpoint of primary patency
was 89.8% (115/128) 95 % CI [83.3%, 94.5%] at 12 months.
CONCLUSION The 12-month outcomes of the BIOFLEX-I study for the Astron stent in
iliac indications demonstrate a low MAE rate, high primary patency, and a low rate of
TLR. This supports the safety and efﬁcacy of the self-expanding, nitinol stent for
treatment of atherosclerotic lesions in the iliac arteries.
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Drug Coated Balloon (DCB) Angioplasty Versus Conventional Angioplasty for the
Treatment of the Superﬁcial Femoral Artery and PI-Segment In Pad-Patients -
Updated Interim Results Of The Freeride Study
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BACKGROUND The use of paclitaxel coated DCB during percutaneous transluminal
angioplasty (PTA) treatment of the femoropopliteal lesions in PAD patients might
result in a signiﬁcant reduced restenosis rate. Thus, the FREERIDE study investigates
the inhibition of restenosis by the FREEWAY DCB versus plain balloon (POBA) in the
treatment of occluded or stenotic lesions in the superﬁcial femoral artery (SFA) and
popliteal arteries (PI segment).
METHODS 280 patients will be randomized either to FREEWAY DCB or to POBA in
23 centers worldwide. The primary endpoint is clinically driven target lesion
revascularization rate (TLR) at 6 months. Secondary endpoints include late lumen
loss and patency rate at 6 months, TLR at 12 and 24 months follow up (FU),
improvement in Rutherford classiﬁcation and Ankle-Brachial index (ABI) and MAE.
RESULTS Until today over 100 patients have been enrolled, over 80 of them
completed the 6 month FU. At 6 months FU positive trends are observed for the TLR
rate (7.1 % vs. 16.7 % after POBA) and MAE (7.1 % vs 23.4 % after POBA). Furthermore
there are positive trends in the patency rate and in the improvement of Rutherford
classiﬁcation after FREEWAY PTA vs. POBA.
CONCLUSION The continuously updated interim results indicate that FREEWAY
DCB might provide an advantage for angioplasty in SFA and PI-segment lesions.
DCB might overcome the existing limitations in the treatment of peripheral
disease.
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Randomized Clinical Trial Favors the Use Of Drug-coated Balloons Over Plain
Balloons for the Postdilatation of Nitinol Stents in the SFA and PI Segment to
Lower Restenosis Rate
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BACKGROUND Stents are needed in up to 50 % of all peripheral interventions where
PTA with plain or drug-coated balloons alone will not reopen the vessel sufﬁciently.
Nevertheless, the restenosis rate of stents is still a major limitation of peripheral
arterial interventions. Drug-coated balloons potentially overcome the problem of in-
stent restenosis when used for postdilatation after primary nitinol stenting in the SFA
and PI segment.
METHODS The Freeway Stent Study is a prospective, randomized, international trial
started in 15 centers in Germany and Austria. 200 patients will be enrolled and ran-
domized equally to primary nitinol stenting followed by either DCB (Freeway) or
plain balloon postdilatation. Primary endpoint is clinically driven target lesion
revascularization (TLR) at 6 months, secondary endpoints include further clinical and
safety evaluations like shift in Rutherford classiﬁcation and ABI, LLL, patency rate
and MAE.
RESULTS Over 170 patients have been enrolled to date, of which over 130 have
ﬁnished the 6 months and 100 the 12 months follow-up. The results highly favor the
use of Freeway DCB over plain balloon based on clinically driven TLR (only 2.9 % vs.
11.9 % at 6 months and 9.1 % vs. 18.0 % at 12 months). This is supported by a sta-
tistically signiﬁcant better clinical outcome for PAD patients treated with DCB as
postdilatation device regarding primary patency rate, ABI and Rutherford classiﬁca-
tion at six months.
CONCLUSION The use of DCB as postdilatation device is investigated in a new
approach to decrease the restenosis rate after nitinol stenting in the SFA and PI
segment. The latest interim results of the Freeway Stent Study show that DCB might
signiﬁcantly lower the in-stent restenosis rate in the treatment of PAD patients.CRT-306
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BACKGROUND Peripheral vascular interventions frequently employ guiding sheaths
with hydrophilic coatings raising the concern for the embolization of this material
clinically as increasingly documented.
METHODS A peripheral stent and delivery system (SDS) were deployed in the iliac
and/or carotid arteries of 23 Yucatan miniswine via femoral or carotid artery access.
SDS were deployed through a Cook

Flexor Ansel Guiding Sheath with a hydrophilic
coating (AQ

hydrophilic coating). In one non-stented control animal, only the guiding
sheath was advanced. Animals were euthanized at 3, 30, 90 & 180 days
post intervention and brains removed for histopathology. In addition, coating material
from the surface of a non-deployed guiding sheath was examined microscopically.
RESULTS The coated guiding sheath was associated with intravascular accumulation
of an amorphous, non-refractile, non-crystalline, and non-birefringent embolic
foreign material in sections of porcine brain which, on H&E staining, appeared lightly
basophilic and slightly stippled. Material was observed at all time points and in all
major regions of the brain, involving 52% of all test animals, and in the non-stented
control animal. The incidence of embolic material was higher (63%) with carotid ac-
cess than femoral access (20%). Evidence of adverse effects related to embolized
material was limited to a single incidence of focally extensive chronic infarction in
one brain.
In vitro incubation of the coated guiding sheath was associated with progressive
separation and sloughing of its hydrophilic coating. Microscopic assessment of
the sloughed hydrophilic coating was interpreted to be morphologically consistent
with the emboli observed in the brains of animals exposed to the coated guiding
sheath.
CONCLUSIONS The hydrophilic coating of Cook

Flexor Ansel Guiding Sheaths
sloughed and embolized to the brain during deployment in a porcine model. Based on
the increased reporting of embolic events involving hydrophilic coatings of inter-
ventional devices, further monitoring, documentation, and consideration of the
potential side-effects of this embolized material in clinical scenarios is warranted.
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Gender Differences in Patients with Lower Extremity Peripheral Artery Disease
Referred for Endovascular Intervention
David J. Carruthers, Adam A. Harris, Mallory P. Barnett, B. Corbett Walsh,
Anvar Babaev, Michael Attubato, Binita Shah
New York University, New York, NY
BACKGROUND Lower extremity peripheral artery disease (PAD) affects approxi-
mately 8 million people in the US. Endovascular intervention is frequently performed
in patients with symptomatic PAD. However, gender differences in patients referred
for endovascular intervention are not well deﬁned.
METHODS We retrospectively analyzed 530 patients who were referred for peripheral
angiography at a tertiary care center in 2013. Patients were followed up for a
median of 11.3 months. Outcomes of interest included extent of disease on semi-
quantitative peripheral angiography, type of procedural intervention, and target
vessel revascularization.
RESULTS Of the 530 patients, 320 (60.4%) were men and 210 (39.6%) were women.
Demographic and clinical characteristics are presented in Table 1. The majority of
patients underwent endovascular intervention (men 76% vs women 80%, p¼0.29).
Outcomes of interest are presented in Table 2.
CONCLUSION In a contemporary cohort of patients referred for endovascular inter-
vention, despite fewer clinical comorbidities in women, there were no signiﬁcant
gender differences in burden of PAD or procedural outcomes.
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RTable 1Men (n[320) Women (n[230) p-valueAge (years) 69.9 [62.25-78.0] 73.33 [66.0-80.25] 0.35Race (%) <0.001White 70.3 46.4Black 7.2 23.0Hispanic 19.7 26.3Asian 0.6 1.4Other 2.2 2.9Body mass index (kg/m2) 28.2 [25.0-27.4] 28.4 [27.4-30.5] 0.89Medical history (%)Diabetes mellitus 51.6 53.3 0.64Hypertension 83.7 89.0 0.004Hyperlipidemia 80.0 84.3 0.16Coronary artery disease 64.0 50.0 0.002Prior peripheral artery revascularization 24.1 24.3 1.00Tobacco use 27.4 11.8 <0.001Medication use (%)Aspirin 57.5 49.5 0.60Clopidogrel 51.9 45.7 0.84Cilostazol 11.6 5.7 0.06Statin 63.4 53.8 0.43Insulin 17.8 12.9 0.81Laboratory dataWhite blood cell count (x 103 cells/mL) 7.7 [6.2-8.9] 10.3 [6.0-9.1] 0.99Neutrophil/lymphocyte ratio 2.86 [1.65-3.50] 1.97 [1.65-3.53] 0.70Platelet count (x 103 cells/uL) 214 [170-250] 259 [192-309] <0.001Creatinine (mg/dL) 1.38 [0.90-1.30] 1.17 [0.71-1.60] <0.001LDL-cholesterol (mg/dL) 86 [62-104] 92 [64-116] 0.14HDL-cholesterol (mg/dL) 46 [36-53] 55 [44-78] <0.001Triglycerides (mg/dL) 149 [92-187] 130 [81-200] 0.015Glucose (mg/dL) 132 [90-149] 129 [89-149] 0.99Resting ankle-brachial index (ABI)Right 0.75 [0.69-0.98] 0.67 [0.41-0.97] 0.10Left 0.79 [0.65-1.03] 0.56 [0.59-0.99] 0.07Critical limb ischemia with ABI <0.4 (%) 42.8 42.4 0.93Continuous data are presented as median [interquartile range]
Table 2Men (n[320) Women (n[230) p-valueExtent of disease (%) 0.74Mild or moderate disease 12.5 10.5Isolated severe suprapopliteal disease 31.3 32.4Isolated severe infrapopliteal disease 15.6 13.3Severe multilevel disease 40.6 43.8Men (n¼243) Women (n¼168)
Type of procedural intervention (%)Stent placement 59.3 54.8 0.42Use of adjunctive device therapy
(e.g. atherectomy, re-entry device)33.3 36.9 0.46Target vessel revascularization (%) 11.9 16.3 0.16CRT-308
Minimal Plaque Surface Area and Minimal Luminal Area Needed for Effective
Atherectomy using the JetStream Navitus in Treating In-Stent Restenosis of
Femoral Artery in a Porcine Model
Nicolas W. Shammas,1 Nicole Aasen,2 Lynn Bailey,3 Jay Budrewicz,3 Trent Farago,2
Gary Jarvis2
1Midwest cardiovascular Research Foundation, Davenport, IA; 2Boston Scientiﬁc,
Maple Grove, MN; 3CBSET, Inc, Lexington, MA
BACKGROUND The JetStream Navitus (JS) atherectomy device is a rotational cutter
with aspiration capability designed to treat infrainguinal arterial obstructive disease.
JS XC can be operated with blades down (BD) (2.1 or 2.4 mm perimeter) or blades up
(BU) (3.0 or 3.4 mm perimeter) to treat femoropopliteal obstructive disease. It is
unclear whether an orbital effect is present while operating the JS leading to a largerminimal luminal area (MLA) than predicted based on device size. Also, the minimum
MLA and plaque surface area (PSA) needed in a typical size femoral artery (5-6 mm)
for the device to be effective has not been deﬁned. Using an in-stent restenosis (ISR)
porcine model and intravascular ultrasound (IVUS) assessment of lesions these
questions were addressed.
METHOD 4 pigs (8 limbs) were implanted with overlapping SMART (Cordis) nitinol
self-expanding stents using an overstretch balloon/stent model. ISR was treated 1
month after stent implantation with an initial 2 blades down (BD) runs followed by
4 BU runs. IVUS measurements were performed at baseline, after 2 BD runs, and
after each BU run on a total of 24 lesions. Minimal luminal area (MLA, mm2) and
plaque surface area (PSA, %) were obtained. 1-sample Wilcoxon signed-rank test
was performed between MLA obtained after BU runs and theoretical maximal MLA
of the XC 2.4-3.4 cutter with BU. MLA and PSA at baseline were plotted against net
MLA and PSA gain (BU - baseline) respectively. The minimum MLA and PSA at
baseline needed for a positive increase in MLA and reduction in PSA were
determined.
RESULTS The femoral artery mean diameter was 4.7 mm. A strong correlation was
present between MLA at baseline and after BU runs (Pearson correlation p¼0.006) and
between PSA at baseline and after BU runs (p<0.0001). An approximateMLA9.0mm2
or PSA  60% were needed to see a positive effect of atherectomy on treated lesion
(i.e. increase in MLA or reduction in PSA). Theoretical MLA achievable from the XC
BU 2.4-3.4 device is 9.08 mm2 (A ¼ pr2 using r¼3.4/2¼1.7mm). No difference is
seen between this calculated MLA and the IVUS measured MLAs after BU
runs using 1-sample Wilcoxon test indicating no orbital effect of the device on tissue
cutting.
CONCLUSION JS XC 2.4-3.4 BU achieved positive cutting of ISR tissue inside a 4.7 mm
femoral artery when the baseline lesion MLA was  9.0 mm2 or PSA  60% on IVUS.
No orbital cutting was seen with the JS BU as MLA obtained after treatment was not
different from theoretical MLA.CRT-309
Impact of Duration of Statin Medication on Clinical Outcomes in Patients
Undergoing Percutaneous Transluminal Angioplasty for Atherosclerotic
Peripheral Arterial Disease
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BACKGROUND Recently, it was reported that statins are associated with lower rates
of major adverse cardiovascular events and amputations in critical limb ischemia
(CLI) patients (pts). However, the impact of statin administration duration on clinical
outcomes for pts undergoing percutaneous transluminal angioplasty (PTA) due to
peripheral arterial disease (PAD) is uncertain.
METHODS A total 286 pts underwent PTA for PAD from Oct 2004 to Feb 2013 from
prospective PTA registry was enrolled. Major adverse cardiovascular and extremity
events (MACEEs) were deﬁned as the composite end-point consisted of cardiac death,
myocardial infarction, repeat PTA, and amputation. The incidence of MACEEs ac-
cording to statin duration up to 1-year was evaluated.
RESULTS The incidences of total MACEEs was in 33.2% (95/286 pts); cardiac death 7
(2.4%), myocardial infarction 3 (1.0%), major and minor amputation 56 (19.6%), repeat
PTA 46 (16.1%). Not only the univariate logistic regression analysis, but also in
multivariate logistic regression adjusted by age, gender, hypertension, diabetes, ce-
rebrovascular accident, and chronic renal failure, there was signiﬁcant risk reduction
for MACEES in statin use duration 180 and 360 days group, not in statin use duration
30 and 90 days (Table).
CONCLUSIONS In our study, prolonged statin duration at least longer than 6 months
was associated with reduced risk of MACEES compared with shorter statin duration in
pts undergoing PTA for PAD.
